The University of Texas at Austin, College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery, Austin, TX, United States.
The University of Texas at Austin, College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery, Austin, TX, United States; Medical Research Core Facility and Platforms, King Abdullah International Medical Research Center/King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdulaziz Medical City (KAMC), NGHA, Riyadh, 11426, Saudi Arabia.
J Control Release. 2018 Dec 28;292:111-118. doi: 10.1016/j.jconrel.2018.10.020. Epub 2018 Oct 16.
Intranasal vaccination using dry powder vaccine formulation represents an attractive, non-invasive vaccination modality with better storage stability and added protection at the mucosal surfaces. Herein we report that it is feasible to induce specific mucosal and systemic antibody responses by intranasal immunization with a dry powder vaccine adjuvanted with an insoluble aluminum salt. The dry powder vaccine was prepared by thin-film freeze-drying of a model antigen, ovalbumin, adsorbed on aluminum (oxy)hydroxide as an adjuvant. Special emphasis was placed on the characterization of the dry powder vaccine formulation that can be realistically used in humans by a nasal dry powder delivery device. The vaccine powder was found to have "passable" to "good" flow properties, and the vaccine was uniformly distributed in the dry powder. An in vitro nasal deposition study using nasal casts of adult humans showed that around 90% of the powder was deposited in the nasal cavity. Intranasal immunization of rats with the dry powder vaccine elicited a specific serum antibody response as well as specific IgA responses in the nose and lung secretions of the rats. This study demonstrates the generation of systemic and mucosal immune responses by intranasal immunization using a dry powder vaccine adjuvanted with an aluminum salt.
鼻腔内接种使用干粉疫苗制剂代表了一种有吸引力的、非侵入性的接种方式，具有更好的储存稳定性，并在黏膜表面增加了保护作用。在此，我们报告称，通过鼻腔内免疫接种用不溶性铝盐佐剂的干粉疫苗，可以诱导特异性黏膜和全身抗体应答。干粉疫苗是通过将模型抗原卵清蛋白吸附在作为佐剂的铝（氧）氢氧化物上，然后通过薄膜冷冻干燥制备的。特别强调了可以通过鼻腔干粉输送装置在现实中用于人类的干粉疫苗制剂的特性。研究发现，疫苗粉末具有“可接受”到“良好”的流动性能，并且疫苗在干粉中均匀分布。使用成人鼻腔铸型进行的体外鼻腔沉积研究表明，约 90%的粉末沉积在鼻腔中。用干粉疫苗对大鼠进行鼻腔内免疫接种，可引起大鼠血清中特异性抗体以及鼻和肺分泌物中特异性 IgA 应答。这项研究证明了使用铝盐佐剂的干粉疫苗进行鼻腔内免疫接种可产生全身和黏膜免疫应答。
